Trade GlaxoSmithKline PLC - GSKl CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.040 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.028007% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.015829% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.1 | ||||||||
Currency | GBP | ||||||||
Margin | 20% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
GSK plc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 14.13 |
Open* | 14.095 |
1-Year Change* | -15.04% |
Day's Range* | 14.095 - 14.26 |
52 wk Range | 12.81-18.43 |
Average Volume (10 days) | 10.55M |
Average Volume (3 months) | 169.95M |
Market Cap | 57.85B |
P/E Ratio | 14.25 |
Shares Outstanding | 4.09B |
Revenue | 31.48B |
EPS | 0.99 |
Dividend (Yield %) | 7.07714 |
Beta | 0.56 |
Next Earnings Date | Feb 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 30, 2023 | 14.130 | 0.145 | 1.04% | 13.985 | 14.260 | 13.985 |
Jan 27, 2023 | 14.100 | 0.065 | 0.46% | 14.035 | 14.215 | 14.035 |
Jan 26, 2023 | 14.025 | 0.040 | 0.29% | 13.985 | 14.140 | 13.980 |
Jan 25, 2023 | 13.995 | 0.040 | 0.29% | 13.955 | 14.040 | 13.920 |
Jan 24, 2023 | 13.930 | -0.150 | -1.07% | 14.080 | 14.125 | 13.835 |
Jan 23, 2023 | 14.120 | 0.075 | 0.53% | 14.045 | 14.170 | 14.040 |
Jan 20, 2023 | 14.035 | -0.160 | -1.13% | 14.195 | 14.195 | 14.005 |
Jan 19, 2023 | 14.165 | 0.095 | 0.68% | 14.070 | 14.215 | 14.025 |
Jan 18, 2023 | 14.130 | -0.155 | -1.09% | 14.285 | 14.290 | 14.015 |
Jan 17, 2023 | 14.375 | 0.010 | 0.07% | 14.365 | 14.400 | 14.275 |
Jan 16, 2023 | 14.375 | 0.150 | 1.05% | 14.225 | 14.400 | 14.225 |
Jan 13, 2023 | 14.365 | 0.270 | 1.92% | 14.095 | 14.415 | 14.095 |
Jan 12, 2023 | 14.325 | 0.205 | 1.45% | 14.120 | 14.330 | 14.090 |
Jan 11, 2023 | 14.095 | 0.010 | 0.07% | 14.085 | 14.245 | 14.065 |
Jan 10, 2023 | 14.110 | 0.115 | 0.82% | 13.995 | 14.195 | 13.995 |
Jan 9, 2023 | 14.220 | -0.085 | -0.59% | 14.305 | 14.320 | 14.100 |
Jan 6, 2023 | 14.285 | 0.095 | 0.67% | 14.190 | 14.390 | 14.165 |
Jan 5, 2023 | 14.310 | 0.170 | 1.20% | 14.140 | 14.375 | 14.140 |
Jan 4, 2023 | 14.430 | -0.080 | -0.55% | 14.510 | 14.670 | 14.405 |
Jan 3, 2023 | 14.495 | 0.310 | 2.19% | 14.185 | 14.675 | 14.185 |
GlaxoSmithKline PLC Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
Revenue | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
Cost of Revenue, Total | 8898 | 9317 | 9572 | 10168 | 10890 | 11427 |
Gross Profit | 18991 | 20869 | 21249 | 23586 | 23209 | 22687 |
Total Operating Expense | 25291 | 26005 | 25335 | 26793 | 26316 | 27949 |
Selling/General/Admin. Expenses, Total | 8859 | 9341 | 9408 | 10671 | 10717 | 10225 |
Research & Development | 3468 | 3862 | 3726 | 4338 | 4603 | 4776 |
Depreciation / Amortization | 41 | 45 | 44 | 64 | 76 | 101 |
Interest Expense (Income) - Net Operating | 3664 | 2139 | 1839 | -128 | 1220 | 1073 |
Unusual Expense (Income) | 782 | 1666 | 1038 | 2051 | -807 | 772 |
Other Operating Expenses, Total | -421 | -365 | -292 | -371 | -383 | -425 |
Operating Income | 2598 | 4181 | 5486 | 6961 | 7783 | 6165 |
Interest Income (Expense), Net Non-Operating | -628 | -646 | -602 | -708 | -432 | -1317 |
Other, Net | -31 | -10 | -84 | -32 | -383 | 594 |
Net Income Before Taxes | 1939 | 3525 | 4800 | 6221 | 6968 | 5442 |
Net Income After Taxes | 1062 | 3247 | 3921 | 5268 | 6388 | 5096 |
Minority Interest | -150 | -637 | -423 | -623 | -639 | -711 |
Net Income Before Extra. Items | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
Net Income | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
Income Available to Common Excl. Extra. Items | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
Income Available to Common Incl. Extra. Items | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
Dilution Adjustment | 1.074 | 0 | ||||
Diluted Net Income | 913.074 | 1532 | 3623 | 4645 | 5749 | 4385 |
Diluted Weighted Average Shares | 4909 | 4941 | 4971 | 5016 | 5038 | 5065 |
Diluted EPS Excluding Extraordinary Items | 0.186 | 0.52823 | 0.70368 | 0.92604 | 1.14113 | 0.86575 |
Dividends per Share - Common Stock Primary Issue | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
Diluted Normalized EPS | 0.32758 | 0.94697 | 0.85456 | 1.35566 | 0.9736 | 0.87285 |
Total Extraordinary Items | -1078 | 125 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 7418 | 8092 | 9077 | 9527 | 9780 |
Revenue | 7418 | 8092 | 9077 | 9527 | 9780 |
Cost of Revenue, Total | 2411 | 2519 | 2822 | 3675 | 3645 |
Gross Profit | 5007 | 5573 | 6255 | 5852 | 6135 |
Total Operating Expense | 5725 | 6453 | 7139 | 8632 | 6979 |
Selling/General/Admin. Expenses, Total | 2315 | 2498 | 2504 | 2908 | 2681 |
Research & Development | 1077 | 1165 | 1169 | 1363 | 1154 |
Depreciation / Amortization | 26 | 25 | 25 | 25 | 23 |
Unusual Expense (Income) | -13 | 323 | 735 | 796 | -385 |
Other Operating Expenses, Total | -91 | -77 | -116 | -135 | -139 |
Operating Income | 1693 | 1639 | 1938 | 895 | 2801 |
Interest Income (Expense), Net Non-Operating | -175 | -169 | -190 | -189 | -203 |
Net Income Before Taxes | 1518 | 1470 | 1748 | 706 | 2598 |
Net Income After Taxes | 1260 | 1538 | 1368 | 930 | 2167 |
Minority Interest | -187 | -143 | -200 | -181 | -365 |
Net Income Before Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Net Income | 1073 | 1395 | 1168 | 749 | 1802 |
Income Available to Common Excl. Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Income Available to Common Incl. Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Dilution Adjustment | 0 | ||||
Diluted Net Income | 1073 | 1395 | 1168 | 749 | 1802 |
Diluted Weighted Average Shares | 5037 | 5060 | 5060 | 5074 | 5068 |
Diluted EPS Excluding Extraordinary Items | 0.21302 | 0.27569 | 0.23083 | 0.14762 | 0.35556 |
Dividends per Share - Common Stock Primary Issue | 0.19 | 0.19 | 0.19 | 0.23 | 0.14 |
Diluted Normalized EPS | 0.19873 | 0.25375 | 0.3419 | 0.22566 | 0.2717 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 16711 | 15907 | 16927 | 19491 | 20247 | 18674 |
Cash and Short Term Investments | 4986 | 3911 | 3958 | 4786 | 6370 | 4335 |
Cash | 1462 | 826 | 569 | 795 | 1762 | 1427 |
Short Term Investments | 3524 | 3085 | 3389 | 3991 | 4608 | 2908 |
Total Receivables, Net | 5917 | 5950 | 6322 | 7148 | 7264 | 8031 |
Accounts Receivable - Trade, Net | 4679 | 4693 | 5185 | 5494 | 5562 | 6258 |
Total Inventory | 5102 | 5557 | 5476 | 5947 | 5996 | 5783 |
Prepaid Expenses | 335 | 308 | 330 | 316 | 359 | 315 |
Other Current Assets, Total | 371 | 181 | 841 | 1294 | 258 | 210 |
Total Assets | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
Property/Plant/Equipment, Total - Net | 10808 | 10860 | 11058 | 11314 | 11006 | 10672 |
Property/Plant/Equipment, Total - Gross | 22164 | 21719 | 22488 | 22565 | 22313 | 21518 |
Accumulated Depreciation, Total | -11356 | -10859 | -11430 | -11251 | -11307 | -10846 |
Goodwill, Net | 5965 | 5734 | 5789 | 10562 | 10597 | 10552 |
Intangibles, Net | 18776 | 17562 | 17202 | 30955 | 29824 | 30079 |
Long Term Investments | 1248 | 1101 | 1558 | 2151 | 3424 | 2214 |
Note Receivable - Long Term | 886 | 875 | 816 | 893 | 858 | 935 |
Other Long Term Assets, Total | 4687 | 4342 | 4716 | 4326 | 4475 | 5977 |
Total Current Liabilities | 19001 | 26569 | 22491 | 24050 | 22148 | 23670 |
Accounts Payable | 3596 | 3528 | 3645 | 4144 | 4357 | 4535 |
Accrued Expenses | 6444 | 6929 | 8535 | 9111 | 9753 | 11186 |
Notes Payable/Short Term Debt | 1426 | 765 | 4420 | 5020 | 1145 | 802 |
Current Port. of LT Debt/Capital Leases | 2703 | 2060 | 1373 | 1898 | 2580 | 2799 |
Other Current Liabilities, Total | 4832 | 13287 | 4518 | 3877 | 4313 | 4348 |
Total Liabilities | 57957 | 56449 | 53706 | 68287 | 65844 | 64048 |
Total Long Term Debt | 14661 | 14264 | 20271 | 23590 | 23425 | 20572 |
Long Term Debt | 14620 | 14221 | 20227 | 22580 | 22538 | 19760 |
Capital Lease Obligations | 41 | 43 | 44 | 1010 | 887 | 812 |
Deferred Income Tax | 1934 | 1396 | 1156 | 3810 | 3600 | 3556 |
Minority Interest | 3839 | 3557 | -688 | 6952 | 6221 | 6287 |
Other Liabilities, Total | 18522 | 10663 | 10476 | 9885 | 10450 | 9963 |
Total Equity | 1124 | -68 | 4360 | 11405 | 14587 | 15055 |
Common Stock | 1342 | 1343 | 1345 | 1346 | 1346 | 1347 |
Additional Paid-In Capital | 2954 | 3019 | 3091 | 3174 | 3281 | 3301 |
Retained Earnings (Accumulated Deficit) | -3263 | -4348 | -8 | 6659 | 8884 | 10073 |
ESOP Debt Guarantee | -286 | -400 | -161 | -135 | -195 | -28 |
Unrealized Gain (Loss) | 380 | 329 | 140 | 409 | 1302 | 383 |
Other Equity, Total | -3 | -11 | -47 | -48 | -31 | -21 |
Total Liabilities & Shareholders’ Equity | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
Total Common Shares Outstanding | 4910.11 | 4957.95 | 4922.93 | 4953.23 | 5029.98 | 5031.81 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 18524 | 17566 | 18254 | 18674 | 28988 |
Cash and Short Term Investments | 4817 | 3562 | 3514 | 4335 | 13977 |
Cash & Equivalents | 4757 | 3503 | 3453 | 4274 | 10967 |
Short Term Investments | 60 | 59 | 61 | 61 | 3010 |
Total Receivables, Net | 7183 | 7507 | 8284 | 8346 | 8797 |
Accounts Receivable - Trade, Net | 6492 | 6902 | 7697 | 7860 | 8300 |
Total Inventory | 6216 | 6330 | 6244 | 5783 | 6003 |
Other Current Assets, Total | 308 | 167 | 212 | 210 | 211 |
Total Assets | 78079 | 77011 | 78689 | 79103 | 89689 |
Property/Plant/Equipment, Total - Net | 10633 | 10589 | 10667 | 10672 | 10704 |
Goodwill, Net | 10442 | 10435 | 10582 | 10552 | 10705 |
Intangibles, Net | 29418 | 29333 | 30241 | 30079 | 30468 |
Long Term Investments | 3755 | 3235 | 2818 | 2214 | 1739 |
Other Long Term Assets, Total | 5307 | 5853 | 6127 | 6912 | 7085 |
Total Current Liabilities | 20275 | 21387 | 22417 | 23670 | 24278 |
Payable/Accrued | 14610 | 14267 | 15230 | 17554 | 17577 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 3172 | 5041 | 4869 | 3601 | 4102 |
Other Current Liabilities, Total | 2493 | 2079 | 2318 | 2515 | 2599 |
Total Liabilities | 63214 | 61634 | 63263 | 64048 | 73508 |
Total Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
Deferred Income Tax | 3566 | 3587 | 3666 | 3556 | 3668 |
Minority Interest | 6145 | 6201 | 6322 | 6287 | 6451 |
Other Liabilities, Total | 10181 | 10017 | 10122 | 9963 | 9885 |
Total Equity | 14865 | 15377 | 15426 | 15055 | 16181 |
Common Stock | 1346 | 1347 | 1347 | 1347 | 1347 |
Additional Paid-In Capital | 3296 | 3299 | 3300 | 3301 | 3436 |
Retained Earnings (Accumulated Deficit) | 10223 | 10731 | 10779 | 10407 | 11398 |
Total Liabilities & Shareholders’ Equity | 78079 | 77011 | 78689 | 79103 | 89689 |
Total Common Shares Outstanding | 5031.39 | 5031.68 | 5031.74 | 5031.81 | 5083.9 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 1062 | 2169 | 4046 | 5268 | 6388 | 5096 |
Cash From Operating Activities | 6497 | 6918 | 8421 | 8020 | 8441 | 7952 |
Cash From Operating Activities | 978 | 988 | 954 | 1231 | 1214 | 1195 |
Amortization | 796 | 934 | 902 | 1103 | 1137 | 1182 |
Non-Cash Items | 1641 | 3072 | 1406 | 2416 | -305 | 1381 |
Cash Taxes Paid | 1609 | 1340 | 1326 | 1512 | 1655 | 1291 |
Cash Interest Paid | 732 | 781 | 766 | 895 | 864 | 786 |
Changes in Working Capital | 2020 | -245 | 1113 | -1998 | 7 | -902 |
Cash From Investing Activities | -1269 | -1443 | -1553 | -5354 | 2161 | -1777 |
Capital Expenditures | -2352 | -2202 | -1796 | -2163 | -2239 | -2931 |
Other Investing Cash Flow Items, Total | 1083 | 759 | 243 | -3191 | 4400 | 1154 |
Cash From Financing Activities | -6392 | -6380 | -6389 | -1840 | -10132 | -7589 |
Financing Cash Flow Items | -1687 | -1475 | -10660 | -1453 | -1950 | -1401 |
Total Cash Dividends Paid | -4850 | -3906 | -3927 | -3953 | -3977 | -3999 |
Issuance (Retirement) of Stock, Net | 15 | -9 | 74 | 51 | 29 | 21 |
Issuance (Retirement) of Debt, Net | 130 | -990 | 8124 | 3515 | -4234 | -2210 |
Foreign Exchange Effects | 283 | -100 | 8 | -82 | -39 | -29 |
Net Change in Cash | -881 | -1005 | 487 | 744 | 431 | -1443 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1260 | 2798 | 4166 | 5096 | 2167 |
Cash From Operating Activities | 331 | 1623 | 4185 | 7952 | 2542 |
Cash From Operating Activities | 361 | 1025 | 2011 | 2377 | 704 |
Non-Cash Items | 433 | 570 | 1140 | 1381 | 634 |
Cash Taxes Paid | 155 | 700 | 857 | 1291 | 213 |
Cash Interest Paid | 95 | 439 | 486 | 786 | 85 |
Changes in Working Capital | -1723 | -2770 | -3132 | -902 | -963 |
Cash From Investing Activities | -48 | -233 | -1416 | -1777 | -3593 |
Capital Expenditures | -354 | -1015 | -2299 | -2931 | -601 |
Other Investing Cash Flow Items, Total | 306 | 782 | 883 | 1154 | -2992 |
Cash From Financing Activities | -1376 | -3421 | -4815 | -7589 | 7973 |
Financing Cash Flow Items | -391 | -883 | -1052 | -1401 | 16 |
Total Cash Dividends Paid | -946 | -2097 | -3048 | -3999 | -952 |
Issuance (Retirement) of Stock, Net | 15 | 19 | 20 | 21 | 12 |
Issuance (Retirement) of Debt, Net | -54 | -460 | -735 | -2210 | 8897 |
Foreign Exchange Effects | -35 | -34 | -21 | -29 | 12 |
Net Change in Cash | -1128 | -2065 | -2067 | -1443 | 6934 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5966 | 229134683 | -34164923 | 2022-07-19 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.1517 | 129037070 | 1316706 | 2022-11-29 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3264 | 95245653 | 977516 | 2023-01-01 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 1.9418 | 79502299 | 0 | 2022-02-27 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2736 | 52145714 | 113556 | 2023-01-01 | LOW |
Silchester International Investors, L.L.P. | Investment Advisor/Hedge Fund | 1.269 | 51954188 | 12827890 | 2022-11-28 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.2107 | 49570121 | -418206 | 2023-01-01 | LOW |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.9198 | 37659407 | -1831852 | 2022-11-28 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.8805 | 36048753 | 1255452 | 2023-01-01 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8358 | 34220716 | -131359 | 2023-01-01 | LOW |
Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.763 | 31239940 | 2050203 | 2023-01-01 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5454 | 22328352 | 526606 | 2022-11-29 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5138 | 21037527 | -869474 | 2022-11-28 | LOW |
Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.4997 | 20457122 | 1270578 | 2022-11-28 | LOW |
Independent Franchise Partners LLP | Investment Advisor | 0.4733 | 19376797 | 6500373 | 2022-11-29 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.464 | 18995200 | -674014 | 2023-01-01 | LOW |
GlaxoSmithKline Plc ESOP | Corporation | 0.4534 | 18564231 | -20616012 | 2021-12-31 | LOW |
Capital Research Global Investors | Investment Advisor | 0.4355 | 17828669 | -58801534 | 2022-11-29 | LOW |
Mondrian Investment Partners Ltd. | Investment Advisor | 0.4144 | 16967070 | -246648 | 2022-11-29 | LOW |
Schweizerische Nationalbank | Bank and Trust | 0.413 | 16908425 | -1156909 | 2022-11-28 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GSK Company profile
GlaxoSmithKline PLC - GSK CFD
GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products.
The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of American depositary shares is listed on the New York Stock Exchange.
GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders.
In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives.
Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.
GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.
GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.
GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’
The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.
Industry: | Pharmaceuticals (NEC) |
980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB
Income Statement
- Annual
- Quarterly
News

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com